Form 4 for CYTK CYTOKINETICS INC
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-26 · accession 0001127602-24-028135 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-26 | 2024-11-26 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $7.96 | +5,300 | 119.2K | +5% | +$42.2K |
| DM | 2024-11-26 | 2024-11-26 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $50.16 | -7,300 | 111.9K | -6% | -$366.2K |
| D | 2024-11-26 | 2024-11-26 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -5,300 | 5,300 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-26 | M | A | 5,300 | $7.96 | 119,178 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-26 | S | D | 5,300 | $50.17 | 113,878 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-26 | S | D | 2,000 | $50.14 | 111,878 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2024-11-26 | M | D | 5,300 | $0.00 | 5,300 | D | $7.96 · 2015-03-26 to 2025-02-26 | 5,300 Common Stock |